There have been two hypothesis: (1) ACEI/ARBs increase the risk for SARS-CoV-2 infection by the upregulation of ACE2 and (2) the therapeutic role of ARBs in COVID-19 in their tissue protective role (due to increased angiotensin 1-7 level) and inhibition of angiotensin II-induced inflammation and acute lung injury [76]. Here, ACE2 is linked to COVID-19.